Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | PHASE2 | COMPLETED | 158 | — | — | Mar 1, 2008 | Oct 1, 2009 | Oct 12, 2015 | 32 | United States, Canada +4 |
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | 0.1 mg/kg every 3 weeks |
| Arm 2 | ACTIVE_COMPARATOR | 1 mg/kg every 3 weeks |
| Arm 3 | ACTIVE_COMPARATOR | 1 mg/kg every 6 weeks |
| Arm 4 | ACTIVE_COMPARATOR | 5 mg/kg every 3 weeks |
| Name | Type | Description |
|---|---|---|
| Anti-CD137 (4-1BB) (BMS-663513) | DRUG | IV solution, IV, until PD or toxicity |
Inclusion Criteria: * Subjects must have been previously treated with one line of systemic anti-cancer therapy (non-experimental or experimental) for metastatic disease, and relapsed, failed to respond (CR or PR) or did not tolerate that regimen. If the treatment has been administered as an adjuvan...